Circulating Tumor DNA Monitoring in Breast Cancer Undergoing Neoadjuvant Therapy
Recruiting
- Conditions
- Stage I-III Breast Cancer
- Registration Number
- NCT05649475
- Lead Sponsor
- Second Affiliated Hospital, School of Medicine, Zhejiang University
- Brief Summary
In the prospective, open, observational study, we aim to evaluate whether circulating tumor DNA (ctDNA) can be the marker of the response to neoadjuvant therapy in stage I-III breast cancer.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
- Patient is ≥ 18 years-old at the time of consent to participate this trial
- Patients with stage I-III invasive breast cancer
- No prior anti-cancer treatment
- Felt to be a possible candidate for neoadjuvant therapy by their physician
Exclusion Criteria
- Known to have other aggressive malignant tumor in the past 5 years.
- Breast cancer during lactation; Inflammatory breast cancer; Acute inflammatory disease, pregnancy and other conditions may affect the levels of ctDNA and/or peripheral inflammatory indicators.
- There are other concomitant diseases that seriously threaten the patient's safety or affect the patient's completion of the study, such as serious infection, liver disease, cardiovascular disease, kidney disease, respiratory disease or uncontrolled diabetes or dyslipidemia.
- The investigator determines that subjects are not appropriate to participate in the study due to other factors.
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Miller-Payne grading system 3 years Residual cancer burden (RCB) 3 years
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of ctDNA clearance are associated with neoadjuvant therapy response in stage I-III breast cancer?
How does ctDNA monitoring compare to traditional imaging in predicting pathological complete response after neoadjuvant chemotherapy for breast cancer?
Which specific biomarkers in ctDNA analysis correlate with recurrence risk in HER2-negative breast cancer patients undergoing neoadjuvant treatment?
What adverse events are associated with liquid biopsy techniques used for ctDNA monitoring in breast cancer clinical trials?
Are there combination therapies with ctDNA-guided approaches that improve outcomes in triple-negative breast cancer compared to standard neoadjuvant regimens?
Trial Locations
- Locations (1)
2nd Affiliated Hospital, School of Medicine, Zhejiang University
🇨🇳Hangzhou, China
2nd Affiliated Hospital, School of Medicine, Zhejiang University🇨🇳Hangzhou, ChinaYiding ChenPrincipal Investigator